Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy

被引:0
|
作者
Sun, Qi [1 ,2 ]
Yang, Yuan-Zhong [1 ,2 ]
Yang, Ping [1 ,2 ]
Li, Yong-Hong [1 ,3 ]
Cao, Yun [1 ,2 ]
Chen, Dong [1 ,3 ]
Zhang, Yijun [1 ,2 ]
机构
[1] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Urol, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
基金
中国国家自然科学基金;
关键词
Prostate cancer; nADT; BCR; Predict; Nomogram; RADICAL PROSTATECTOMY; PTEN LOSS; RISK; CARCINOMA; ADENOCARCINOMA; FLUTAMIDE; OUTCOMES; ACETATE;
D O I
10.1007/s11255-023-03658-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundA predictive model for biochemical recurrence (BCR) of prostate cancer (PCa) after neoadjuvant androgen deprivation therapy (nADT) has not been established. This study was aimed at determining multiparameter variables that could be used to construct a nomogram to predict the post-nADT BCR of PCa.MethodsOverall, 43 radical prostatectomy specimens from PCa patients who had undergone nADT were collected. Multiparameter variables were analyzed by univariate and then multivariate logistic analyses to identify the independent prognostic factors for predicting BCR. The predictive model was established using Lasso regression analysis.ResultsUnivariate logistic analysis revealed six variables, pathology stage; margins; categorization as group A, B, or C; nucleolus grading; percentage of tumor involvement (PTI); and PTEN status were significantly associated with the BCR of PCa (all p < 0.05). Multivariate logistic regression analysis suggested that categorization as group C, severe nucleolus grading, PTI less than or equal to 5%, and PTEN loss were positively correlated with BCR (all p < 0.05). A nomogram comprising the four variables predicting BCR was constructed, and it exhibited good discrimination (AUC: 0.985; specificity: 86.2%; sensitivity: 100%). Calibration plots for the probability of freedom from BCR at 1 and 2 years showed a good match between the prediction by the nomogram.ConclusionsWe constructed and validated a nomogram to predict the risk of BCR in PCa patients after nADT. This nomogram is a complement to the existing risk stratification systems for PCa, which could have marked implications for clinical decision-making for PCa patients after nADT.
引用
收藏
页码:2215 / 2224
页数:10
相关论文
共 50 条
  • [31] Androgen deprivation therapy for prostate cancer
    Bahnson, Robert
    JOURNAL OF UROLOGY, 2007, 178 (04): : 1148 - 1148
  • [32] Androgen deprivation therapy for prostate cancer
    Singer, Eric A.
    Golijanin, Dragan J.
    Miyamoto, Hiroshi
    Messing, Edward M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (02) : 211 - 228
  • [33] Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy
    Lopez-Torrecilla, Jose
    Boladeras, Anna
    Angeles Cabeza, Maria
    Zapatero, Almudena
    Jove, Josep
    Esteban, Luis M.
    Henriquez, Ivan
    Casana, Manuel
    Gonzalez-San Segundo, Carmen
    Gomez-Caamano, Antonio
    Luis Mengual, Jose
    Hervas, Asuncion
    Luisa Munoz, Julia
    Sanz, Gerardo
    STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 (10) : 792 - 800
  • [34] Predictors of Castration Resistant Prostate Cancer After Definitive Radiation Therapy: Impact of Failing Neoadjuvant Androgen Deprivation Therapy
    Spratt, D. E.
    Zumsteg, Z.
    Romesser, P. B.
    Kollmeier, M.
    Polkinghorn, W. R.
    Pei, X.
    Zelefsky, M. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S175 - S175
  • [35] Identification of a prognostic biomarker predicting biochemical recurrence and construction of a novel nomogram for prostate cancer
    Yu, Zhaojun
    Chao, Haichao
    Xu, Fanghua
    Deng, Huanhuan
    Deng, Leihong
    Song, Zhen
    Zeng, Tao
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [36] HSD3B1 genotype and response to androgen deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer.
    Hearn, Jason W. D.
    Xie, Wanling
    Nakabayashi, Mari
    Almassi, Nima
    Reichard, Chad A.
    Pomerantz, Mark
    Kantoff, Philip W.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Abnormal physical performance and frailty in older men with biochemical recurrence of prostate cancer (PCa) on androgen deprivation therapy (ADT)
    Bylow, K. A.
    Hemmerich, J.
    Mohile, S.
    Stadler, W.
    Dale, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer
    Gotto, Geoffrey T.
    Yu, Changhong
    Bernstein, Melanie
    Eastham, James A.
    Kattan, Michael W.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [39] A nomogram for testosterone recovery following combined androgen deprivation therapy and radiation therapy for prostate cancer.
    Spiegel, Daphna
    Hong, Julian C.
    Lee, W. Robert
    Salama, Joseph Kamel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [40] Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Buyyounouski, MK
    Hanlon, AL
    Eisenberg, DF
    Horwitz, EM
    Feigenberg, SJ
    Uzzo, RG
    Pollack, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (05): : 1455 - 1462